CBAY CymaBay Therapeutics Inc

CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.

$2.84  +0.02 (0.53%)
As of 06/27/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/27/2014
Outstanding shares:  84,677,939
Average volume:  1,192,333
Market cap:   $238,791,788
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BJ3WDH3
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.22
PS ratio:   0.00
Return on equity:   -93.33%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy